News

September 24, 2013 | News & Notices RIKEN and Shimadzu Corporation Enters into an Exclusive License Agreement of Energy Resolved Oxonium Ion Monitoring (Erexim) Technology in Glycomics Analysis Services with Mitsubishi Chemical Medience

Mitsubishi Chemical Medience (MCM) announced on September 17, 2013 that the company enters into an exclusive license agreement of Energy Resolved Oxonium Ion Monitoring (Erexim) Technology [PATPEND], jointly-developed by RIKEN and Shimadzu, in glycomics analysis services. By use of Erexim technology, MCM starts up evaluating the usefulness of Glycomics Analysis Services for guiding development and quality management of glycosylated biologics and biosimilars.

For more details, visit the MCM Website.